Suppr超能文献

坏死松解性游走性红斑的病因及发病机制:文献综述

Etiology and pathogenesis of necrolytic migratory erythema: review of the literature.

作者信息

Tierney Emily P, Badger Joanna

机构信息

Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.

出版信息

MedGenMed. 2004 Sep 10;6(3):4.

Abstract

CONTEXT

Necrolytic migratory erythema (NME) is a characteristic skin condition seen in the presence of a pancreatic glucagonoma. The presence of NME in the absence of a pancreatic tumor has been termed the pseudoglucagonoma syndrome. In such cases, NME is commonly associated with conditions, such as liver disease, inflammatory bowel disease, pancreatitis, malabsorption disorders (ie, celiac sprue), and other malignancies. There are many theories on the pathogenesis of NME, which include the direct action of glucagon in inducing skin necrolysis, hypoaminoacidemia-inducing epidermal protein deficiency and necrolysis, a nutritional or metabolic deficiency of zinc or essential fatty acids, liver disease, glucagon induction of inflammatory mediators, a substance secreted from pancreatic and other visceral tumors associated with NME, and generalized malabsorption.

OBJECTIVE

To present a review of the literature on the clinical presentation, etiology, pathogenesis, and treatment of NME.

DESIGN

Review of the literature on NME occurring in patients both with and without a pancreatic glucagonoma.

METHODS

We performed a PubMed review of the literature on the etiology and pathogenesis of NME to identify case reports and reviews published in both the internal medicine and dermatology literature.

RESULTS

Our literature review encompassed 17 primary case reports and literature reviews published in the dermatologic and internal medicine literature on NME in patients both with and without a pancreatic glucagonoma. Although we found no clear consensus among the investigators of a universally accepted pathogenesis for NME, we did identify 4 main categories of etiologic/pathogenetic mechanisms for NME (glucagon excess, nutritional deficiencies, inflammatory mediators, and liver disease) that were discussed by many of the investigators and validated by both clinical and scientific evidence.

CONCLUSION

The exact pathogenesis and treatment of NME remain ill-defined despite many case reports and studies on NME in the literature. The many systemic diseases and nutritional deficiencies that have been found to be associated with NME suggest a multifactorial model for the pathogenesis of the disease. The most comprehensive, postulated mechanism for NME involves a combination of zinc, amino acid, and fatty acid deficiencies (arising from a wide variety of causes, such as dietary insufficiency, malabsorption syndromes, liver disease, elevated glucagon levels, and disorders of metabolism) that contributes to increased inflammation in the epidermis in response to trauma and to the necrolysis observed in NME. The importance of gaining an understanding of the etiology and pathogenesis of NME lies in the fact that there is no universally accepted mechanism of pathogenesis for NME, and that the only treatment reported to resolve the rash in these patients is to adequately identify and treat the underlying associated systemic condition or nutritional deficiency.

摘要

背景

坏死性游走性红斑(NME)是胰腺胰高血糖素瘤患者中出现的一种特征性皮肤状况。在无胰腺肿瘤的情况下出现NME被称为假性胰高血糖素瘤综合征。在这种情况下,NME通常与诸如肝病、炎症性肠病、胰腺炎、吸收不良障碍(即乳糜泻)及其他恶性肿瘤等病症相关。关于NME的发病机制有许多理论,包括胰高血糖素在诱导皮肤坏死溶解中的直接作用、低氨基酸血症诱导的表皮蛋白缺乏和坏死溶解、锌或必需脂肪酸的营养或代谢缺乏、肝病、胰高血糖素诱导的炎症介质、与NME相关的胰腺及其他内脏肿瘤分泌的一种物质以及全身性吸收不良。

目的

对有关NME的临床表现、病因、发病机制及治疗的文献进行综述。

设计

对有或无胰腺胰高血糖素瘤患者中发生的NME的文献进行综述。

方法

我们对PubMed上有关NME病因和发病机制的文献进行了综述,以识别在内科和皮肤科文献中发表的病例报告和综述。

结果

我们的文献综述涵盖了17篇主要病例报告以及皮肤科和内科文献中发表的关于有或无胰腺胰高血糖素瘤患者NME的文献综述。尽管我们发现研究人员对于NME普遍接受的发病机制未达成明确共识,但我们确实确定了NME病因/发病机制的4个主要类别(胰高血糖素过多、营养缺乏、炎症介质和肝病),许多研究人员对此进行了讨论,且有临床和科学证据验证。

结论

尽管文献中有许多关于NME的病例报告和研究,但NME的确切发病机制和治疗仍不明确。已发现与NME相关的多种全身性疾病和营养缺乏提示该疾病的发病机制为多因素模型。关于NME最全面的假设机制涉及锌、氨基酸和脂肪酸缺乏(由多种原因引起,如饮食不足、吸收不良综合征、肝病、胰高血糖素水平升高及代谢紊乱)的综合作用,这会导致表皮对创伤的炎症反应增加以及NME中观察到的坏死溶解。了解NME病因和发病机制的重要性在于,目前尚无被普遍接受的NME发病机制,且据报道,这些患者中唯一能解决皮疹问题的治疗方法是充分识别并治疗潜在的相关全身性疾病或营养缺乏。

相似文献

2
Necrolytic Migratory Erythema: A Forgotten Paraneoplastic Condition.
J Cutan Med Surg. 2017 Nov/Dec;21(6):559-561. doi: 10.1177/1203475417719051. Epub 2017 Jun 29.
3
[Necrolytic migratory erythema].
Rev Med Liege. 1998 Dec;53(12):778-83.
5
Glucagonoma With Necrolytic Migratory Erythema: Metabolic Profile and Detection of Biallelic Inactivation of DAXX Gene.
J Clin Endocrinol Metab. 2018 Jul 1;103(7):2417-2423. doi: 10.1210/jc.2017-02646.
6
7
The glucagonoma syndrome and necrolytic migratory erythema: a clinical review.
Eur J Endocrinol. 2004 Nov;151(5):531-7. doi: 10.1530/eje.0.1510531.
8
[The question of surgical therapy for necrolytic migratory erythema, a cutaneous disease].
Chirurg. 2006 Jun;77(6):535-8. doi: 10.1007/s00104-005-1122-y.
9
Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome.
Clin Endocrinol (Oxf). 2002 Dec;57(6):827-31. doi: 10.1046/j.1365-2265.2002.01660.x.

引用本文的文献

1
A unique case of glucagonoma with atypical necrolytic migratory erythema.
JAAD Case Rep. 2025 Jun 19;63:154-157. doi: 10.1016/j.jdcr.2025.06.009. eCollection 2025 Sep.
2
Necrolytic migratory erythema following prolonged continuous subcutaneous dasiglucagon administration: a rare dermatologic adverse event.
Endocrinol Diabetes Metab Case Rep. 2025 Apr 29;2025(2). doi: 10.1530/EDM-25-0006. Print 2025 Apr 1.
3
Paraneoplastic Dermatoses: A Clue for Underlying Malignancies.
J Clin Med. 2025 Feb 5;14(3):1014. doi: 10.3390/jcm14031014.
4
Annular eruption with weight loss in a 47-year-old man.
Frontline Gastroenterol. 2023 Sep 19;15(2):177-178. doi: 10.1136/flgastro-2023-102507. eCollection 2024 Mar.
5
Hepatic Glucagonoma in a Post-bariatric Female Patient: A Case Report.
Cureus. 2023 Oct 9;15(10):e46724. doi: 10.7759/cureus.46724. eCollection 2023 Oct.
6
Trace element zinc and skin disorders.
Front Med (Lausanne). 2023 Jan 17;9:1093868. doi: 10.3389/fmed.2022.1093868. eCollection 2022.
7
Zinc and Zinc Transporters in Dermatology.
Int J Mol Sci. 2022 Dec 18;23(24):16165. doi: 10.3390/ijms232416165.
8
Lymphocyte-Depleted Hodgkin's Lymphoma in Coeliac Disease: A Diagnostic Challenge During the COVID-19 Pandemic.
Cureus. 2022 Aug 26;14(8):e28432. doi: 10.7759/cureus.28432. eCollection 2022 Aug.
9
Skin manifestations of neuroendocrine neoplasms: review of the literature.
Postepy Dermatol Alergol. 2022 Aug;39(4):656-661. doi: 10.5114/ada.2021.112073. Epub 2022 Jan 18.
10
[Migratory necrolytic erythema as a manifestation of pancreatic neuroendocrine tumor. Clinical-radiological evaluation].
Rev Fac Cien Med Univ Nac Cordoba. 2022 Jun 6;79(2):188-192. doi: 10.31053/1853.0605.v79.n2.32543.

本文引用的文献

1
Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome.
Clin Endocrinol (Oxf). 2002 Dec;57(6):827-31. doi: 10.1046/j.1365-2265.2002.01660.x.
2
3
Necrolytic migratory erythema and zinc deficiency.
Br J Dermatol. 1997 May;136(5):783-5.
4
Acrodermatitis enteropathica, zinc metabolism, copper status, and immune function.
Arch Pediatr Adolesc Med. 1994 Sep;148(9):980-5. doi: 10.1001/archpedi.1994.02170090094017.
5
Necrolytic migratory erythema without glucagonoma in patients with liver disease.
J Am Acad Dermatol. 1995 Apr;32(4):604-9. doi: 10.1016/0190-9622(95)90345-3.
6
Nutritional and hormonal factors influencing desaturation of essential fatty acids.
Prog Lipid Res. 1981;20:41-7. doi: 10.1016/0163-7827(81)90012-6.
7
Clinical and metabolic aspects of glucagonoma.
Medicine (Baltimore). 1980 Mar;59(2):100-13. doi: 10.1097/00005792-198003000-00002.
8
The glucagonoma syndrome: clinical features, diagnosis, and treatment.
Endocr Rev. 1981 Summer;2(3):347-61. doi: 10.1210/edrv-2-3-347.
10
Glucagonoma syndrome: in vitro evidence that glucagon increases epidermal arachidonic acid.
J Am Acad Dermatol. 1984 Sep;11(3):468-73. doi: 10.1016/s0190-9622(84)70192-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验